Literature DB >> 31341722

Immune checkpoint inhibitor-related myositis associated with atezolizumab therapy.

Anthony Khoo1, YiZhong Zhuang1, Karyn Boundy1, Joseph Frasca1.   

Abstract

Entities:  

Year:  2019        PMID： 31341722      PMCID： PMC6615650          DOI： 10.1212/CPJ.0000000000000597

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  6 in total

Review 1.  Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.

Authors:  L Spain; G Walls; M Julve; K O'Meara; T Schmid; E Kalaitzaki; S Turajlic; M Gore; J Rees; J Larkin
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

2.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

Review 3.  A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.

Authors:  Joaquin Bellmunt; Thomas Powles; Nicholas J Vogelzang
Journal:  Cancer Treat Rev       Date:  2017-02-02       Impact factor: 12.111

4.  Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer.

Authors:  Mehdi Touat; Thierry Maisonobe; Samuel Knauss; Omar Ben Hadj Salem; Baptiste Hervier; Karine Auré; Tali-Anne Szwebel; Nora Kramkimel; Claire Lethrosne; Jean-Frédéric Bruch; Pauline Laly; Jacques Cadranel; Nicolas Weiss; Anthony Béhin; Yves Allenbach; Olivier Benveniste; Timothée Lenglet; Dimitri Psimaras; Werner Stenzel; Sarah Léonard-Louis
Journal:  Neurology       Date:  2018-08-08       Impact factor: 9.910

5.  Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Thomas Powles; Ignacio Durán; Michiel S van der Heijden; Yohann Loriot; Nicholas J Vogelzang; Ugo De Giorgi; Stéphane Oudard; Margitta M Retz; Daniel Castellano; Aristotelis Bamias; Aude Fléchon; Gwenaëlle Gravis; Syed Hussain; Toshimi Takano; Ning Leng; Edward E Kadel; Romain Banchereau; Priti S Hegde; Sanjeev Mariathasan; Na Cui; Xiaodong Shen; Christina L Derleth; Marjorie C Green; Alain Ravaud
Journal:  Lancet       Date:  2017-12-18       Impact factor: 79.321

6.  Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity.

Authors:  C Calabrese; E Kirchner; A Kontzias; V Velcheti; L H Calabrese
Journal:  RMD Open       Date:  2017-03-20
  6 in total
  2 in total

Review 1.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

Review 2.  Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Caberry W Yu; Matthew Yau; Natalie Mezey; Ishraq Joarder; Jonathan A Micieli
Journal:  Eye Brain       Date:  2020-11-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.